External Automatic Glaucoma Laser
(EAGLE) for the first-line glaucoma treatment: Commercial prototype development and validation

 

The GLAUrious project is clinically testing and validating the novel External Automatic Glaucoma Laser (EAGLE) device developed and patented by BELKIN Laser Ltd with the goal of providing accessible first-line treatment for glaucoma. About 64 million people worldwide suffer from glaucoma Which is a chronic disease causing progressive optic nerve degeneration, is the leading cause of irreversible blindness globally. Although incurable, disease progression can be arrested or delayed by reducing the pressure inside the eye, thus preventing visual incapacitation and blindness.

 

Current first-line treatment requires life-long daily eye drops, a strict regimen causing 50% patient dropout after 1 year.

About
 

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement

No 720274

News 

Please reload

External Advisory Board Meeting, AAO2018

October 28, 2018

1/5
Please reload

Dear consortium member,
If you wish to have access to the
following information:

  • Meetings

  • Management

  • Deliverables

  • Reports

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement

No 720274

September 22, 2016

Please reload

Last News  

  web design: STUDIO81